IPP Bureau
Honeywell, Recipharm to speed development of inhalers
By IPP Bureau - August 18, 2023
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
BASF, Promega and Swiss TPH collaborate to drive research for malaria control
By IPP Bureau - August 18, 2023
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries
By IPP Bureau - August 17, 2023
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients
By IPP Bureau - August 17, 2023
Jeet will be a trusted partner in cardiovascular care
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
By IPP Bureau - August 17, 2023
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
By IPP Bureau - August 17, 2023
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Cipla launches knowledge sharing platform ‘Ciplamed 2.0’
By IPP Bureau - August 16, 2023
CiplaMed 2.0 leverages advanced analytics and automation
SSI Strategy to acquires NDA Group partner to form global life sciences consultancy
By IPP Bureau - August 16, 2023
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
By IPP Bureau - August 16, 2023
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
By IPP Bureau - August 16, 2023
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
Mobile addicted generation heading towards hearing disorders: Survey
By IPP Bureau - August 16, 2023
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
By IPP Bureau - August 16, 2023
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
By IPP Bureau - August 16, 2023
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression
By IPP Bureau - August 16, 2023
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Exor to buy 15% shareholding in Philips
By IPP Bureau - August 16, 2023
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
